- Home
- AWX vs APRE Comparison
AWX vs APRE Comparison
Compare AWX & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AWX
- APRE
- Stock Information
- Founded
- AWX 1998
- APRE 2006
- Country
- AWX United States
- APRE United States
- Employees
- AWX N/A
- APRE N/A
- Industry
- AWX Environmental Services
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AWX Utilities
- APRE Health Care
- Exchange
- AWX Nasdaq
- APRE Nasdaq
- Market Cap
- AWX 13.6M
- APRE 13.5M
- IPO Year
- AWX 1998
- APRE 2019
- Fundamental
- Price
- AWX $2.76
- APRE $1.75
- Analyst Decision
- AWX
- APRE Strong Buy
- Analyst Count
- AWX 0
- APRE 2
- Target Price
- AWX N/A
- APRE $15.50
- AVG Volume (30 Days)
- AWX 14.2K
- APRE 23.0K
- Earning Date
- AWX 05-07-2025
- APRE 05-13-2025
- Dividend Yield
- AWX N/A
- APRE N/A
- EPS Growth
- AWX N/A
- APRE N/A
- EPS
- AWX 0.34
- APRE N/A
- Revenue
- AWX $83,795,000.00
- APRE $1,502,581.00
- Revenue This Year
- AWX N/A
- APRE N/A
- Revenue Next Year
- AWX N/A
- APRE N/A
- P/E Ratio
- AWX $8.40
- APRE N/A
- Revenue Growth
- AWX 3.58
- APRE 157.63
- 52 Week Low
- AWX $2.00
- APRE $1.74
- 52 Week High
- AWX $3.99
- APRE $6.48
- Technical
- Relative Strength Index (RSI)
- AWX 39.09
- APRE 27.73
- Support Level
- AWX $2.48
- APRE $1.74
- Resistance Level
- AWX $2.90
- APRE $2.30
- Average True Range (ATR)
- AWX 0.18
- APRE 0.15
- MACD
- AWX -0.02
- APRE -0.01
- Stochastic Oscillator
- AWX 31.76
- APRE 10.89
About AWX Avalon Holdings Corporation
Avalon Holdings Corp is a waste management company. The company provides waste management services to industrial, commercial, municipal, and governmental customers in selected northeastern and midwestern U.S. markets. The company has two operating segments. The Waste management services segment which is the key revenue driver, includes waste disposal services, captive landfill operations, and saltwater injection well operations. Its Golf and related operations segment includes management of golf courses and related clubhouses, a hotel, fitness centers, tennis courts, salon and spa services, dining, banquet, and conference facilities.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.